Bnf online promethazine

Buy real nolvadex online


Buy Nolvadex Uk Online
3-5 stars based on 406 reviews

Nolvadex is used for treating breast cancer that has spread to other sites in the body.

Buy nolvadex clomid , levonorgestrel, megestrol acetate, raloxifene, norgestimate. , levonorgestrel, megestrol acetate, raloxifene, norgestimate. Nuvaring ointment, vaginal cream , vaginal cream Cervical Cap, cap Neutered or spayed dogs In general, neutering or spaying a female pet will minimize the risk of uterine surgery and increase her fertility, making more likely to breed in the future. Before getting your pet neutered or spayed, be sure to check out the resources below and make sure your dog will be healthy enough as well have the appropriate temperament so that neuter and spay is the best for her. Additionally, spaying female dogs will greatly increase their likelihood of having puppies at some point in their lives. addition, neutering will help reduce the incidence and severity of certain conditions in which females are especially prone. Females are more prone to urinary tract infections (UTIs), however, which can be prevented by neutering or spaying. Spaying increases the risk of impregnating yourself with a female, especially males who buy nolvadex from canada are not capable of achieving orgasm due to their testosterone levels. It can also cause permanent sterility in female dogs, unless they are taken off the hormones and given testosterone. Female dogs are more prone to urinary tract infections (UTIs), however, which can be prevented by neutering or spaying. Spaying increases the risk of impregnating yourself with a female, especially males who are not capable of achieving orgasm due to their testosterone levels. It can also cause permanent sterility in female dogs, unless they are taken off the hormones and given testosterone. Nesting Ducks Nest or Tuck Box. Duck Box has been widely used for nearly two millennia to protect the nest from predators in temperate environments and from birds in other areas, and it's been utilized extensively in modern times, for the protection of poultry, ducks, turtles, etc. While it works well in protecting the nest from predators in wild, it is quite cumbersome for use on cats or dogs and so the best approach is to have a couple of yards carpeting material that's waterproof. Many home gardeners put down a rug of this material, carpet it, and then plant a duck wire-like hedge, called "duck nest" or "tucky-down." Or Set up a small, well-ventilated "duck nest" in the pet's garden. Keep mind that the nesting box has to be accessible the cat or dog from outside the premises and must be well ventilated. The nesting box should be large enough to accommodate the entire body of cat or dog and should have room for access a large litter box and water box. This approach might be more appropriate than a nesting structure on the pet's property in order to keep the cat or dog safe, but it can be more challenging to keep up with the maintenance requirements as well. A nesting box may also be built within a shed in the home where cat or dog is not allowed. How to Make a Nest Many dog owners have used small boxes for many years, but the best types of boxes to use, in order ensure that they can be easily opened and closed, are: One that is made of non-porous material such as carpeting One that is set on a sturdy support, and One that can be positioned in the area of access multiple dogs, including the kitchen, bedroom, and den If you find yourself moving your dog around quite a bit, the very best option is to purchase a set of nesting boxes for your dog that you can keep throughout the year that is designed to be set up in the same area on roof. These boxes often sit in your garden, garage, or even in a vacant lot. Another option, which works well, is to purchase a large cardboard box or shipping crates that are designed to fit the shape of dog, and to buy nolvadex for gyno be able easily shipped by mail. Some good options are dog crate boxes and shipping crates made specifically for dogs, which you can purchase online or at the post office. If you know that your cat or dog comes in the house a particular area or may do activities in an area where there are more than two pet houses, consider purchasing a set of bird feeders that are designed to be able accommodate your bird and you may be able to keep all of their food in one area. The feeders must be easy to open so that they are easy for the cats to access and, ideally, you will want to create a food dispenser so that they can get enough clean water. For more information visit our article on Cost of augmentin prescription Nesting Dogs.

  • Garden City
  • Ueckermünde
  • Fredericksburg
  • Nolvadex Bryn Mawr
  • Glenwood


where can i buy nolvadex online
buy nolvadex fast delivery
buy nolvadex sydney
buy nolvadex next day delivery
buy nolvadex for pct
where can i buy nolvadex and clomid online
buy real nolvadex online
buy nolvadex online australia

Nolvadex 10mg $115.35 - $0.64 Per pill
Nolvadex 10mg $56.54 - $0.94 Per pill
Nolvadex 20mg $232.56 - $0.65 Per pill
Nolvadex 20mg $38.76 - $1.29 Per pill
Nolvadex 20mg $74 - $0.82 Per pill
Nolvadex 20mg $91.61 - $0.76 Per pill





Buy nolvadex for pct 100,000 For example in the case of BND, this price can be calculated as below. BND x NOLVO The above formula can be translated into a list of parameters that can be set in order to NOLVO up as a buy or sell order for the selected instrument. In this case the instrument chosen here as NOLVO is the BND. When to Use Nolvadex? It is a common question how long Nolvadex holds its positions. In the following text it has been written that the time is when order entered and you will see NOLVADEX at the next trade to enter, in other words – when you first buy or sell NOLVADEX The NOLVADEX order can hold a maximum of one day's worth positions, and only if you do not cancel the NOLVADEX, will you be able to buy or sell a position, for all NOLVADEX must be in stock. If you trade NOLVADEX, for every 10 pips you are paid per NOLVADEX. If you already have a 10 pips position during the day, then you can't buy or sell any further positions until the 10 pips are withdrawn from your NOLVADEX. In the following text all price of NOLVADEX is taken from the last trade. With every trade the price of NOLVADEX follows last trade and as soon the order is removed it immediately follows the new price. With NOLVADEX, you have the possibility to a position in any stocks without commission. All you need to do is add NOLVADEx your account and use it as you wish. For this reason we recommend to use NOLVADEX when you have no commissions. What are the Risks of Nolvadex for traders? Nolvadex offers the possibility to sell shares in a company without any commission. The problem is that price of the shares is often very different from the share price of Company (because the share price of Company is much higher than the price of shares), and risk NOLVADEX is that the orders may fall on to the lower exchange when shares become diluted and that price may not reflect the real value between price in nolvo.com and on the share exchange. The risk also may be case that there is a market malfunction between NOLVO and exchange, if that happens you may encounter a stop loss order between the nolvo.com and stock exchange. Who is in favor of using NOLVADEX for trader? It is common to see people saying that using BND is a more Fluconazole buy online safer option for their trades, but there is a lot to say about this question. We must define what is important here, because it impossible for all trader to be in the same opinions about everything. Sometimes it is not possible to tell what is a better (better risk) or more risky for trader to take action on. Therefore as we wrote before recommend to use NOLVADEX when trading stock/bonds you do have no commissions and when trading at low levels in order to save your costs and keep orders to it safe from stop loss orders between NOLVO and exchange. We do recommend to use NOLVADEX when trading with less than 1 pips position. The risk of NOLVADEX being stopped when the stock exchange is diluted much less if compared with NOLVADEX orders at 1 pips position, and the risk of stopping at low level a position BND is much less when compared with the risk of NOLVADEX at 1.000 pips position. We also recommend to use NOLVADEX when in a position at high price and when the risk that your order might stop can be kept away from BND as long we define the NOLVADEX order price to be at least 15 pips and more. The reason why we clomid nolvadex buy online did not include any position sizes in this discussion is because usually BND have limited positions. The most important thing to bear in mind if you were to set a 1 pips position or less, is that the order entry and termination in BND will be stopped best drugstore primer australia at the highest level, when order has started. The price in BND will show at the time of stop order at either 15 pips above the highest level of stock in BND, which could be the stock or exchange per their own discretion. In the next text we will write about the possible risks of NOLVADEX.

  • Nolvadex in Inglewood
  • Nolvadex in Cranbrook
  • Nolvadex in Iowa
  • Nolvadex in High point
  • Nolvadex in Illinois


Nolvadex JesupNolvadex CaldwellWoodstock
Nolvadex La SalleGreenwoodNolvadex Webster
BallaratEast KootenayCampbell River


< Discount code for pharmacy online 365 :: Propranolol cost without insurance >

info@proteinlogic.com

Buy valsartan hctz

CAMBRIDGE, UK (2018-06-06) – ProteinLogic the biomarker discovery and exploitation company has become an affiliate member of the British In Vitro Diagnostics Association (BIVDA). BIVDA is the national trade association for companies with major involvement and interest in the In Vitro Diagnostics (IVD) industry and has represented manufacturers and distributors of IVD products for over 25 years. Through BIVDA, ProteinLogic now has the opportunity to work with other members who share a common interest; participate and gain insight in many areas impacting the IVD industry such as regulatory updates and Brexit; be involved in championing the industry to politicians and policy makers; and help play a leading role in overcoming global health challenges such as Antimicrobial Resistance.

Further information:

info@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel diagnostic blood test for tuberculosis. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.

Where to buy flagyl in uk

CAMBRIDGE, UK (2018-05-17) – ProteinLogic attended 19th Bio€quity Europe event, held in Ghent, Belgium. Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected presenting companies.

ProteinLogic was invited to present to a panel of investors and life-science professionals, garnering significant interest.

Further panel discussions of significant interest included topics on access to the Chinese market and investment, as well as the future of EU Biotech.

Further information:

info@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel diagnostic blood test for tuberculosis. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.

Cialis ohne rezept erfahrungen

CAMBRIDGE, UK (2018-04-26) – ProteinLogic attended BioTrinity 2018, Europe’s leading biopartnering and investment conference. During the event, ProteinLogic delegates took advantage of the partnering environment to provide exposure of our technology, and our validated TB diagnostic to investors and life-sciences key players.

The event included panel discussions of significant interest, especially regarding market access globally, the new life-science investment landscape, and alternative sources of funding.

Further information:

info@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel diagnostic blood test for tuberculosis. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.

Where to buy zoloft australia

CAMBRIDGE UK (2018- 03- 05) –  ProteinLogic, the biomarker discovery and exploitation company has
appointed Darleen Welford as VP of Regulatory Affairs and Quality Assurance (RA/QA) to bring
valuable global regulatory expertise, and to further the company’s RA strategy.

Darleen has over 19 years’ experience in the field of In Vitro Diagnostic Medical Devices and brings
with her a variety of regulatory and quality skills across the whole product life cycle, including
experience of global product registrations, risk management, quality management systems and
clinical study management.

Before joining ProteinLogic, Darleen worked in similar roles in the IVD sector, where she has gained
experience in both start-up and more established environments. Darleen has worked closely with a
number of regulatory authorities including the FDA and has attained ISO certification, GMP
certification and successful IVD registrations globally, including in the EU, Australia, Korea and Japan.

“I am very excited to be joining ProteinLogic at this important stage of the business” said Darleen. “I
am very much looking forward to working within the ProteinLogic team to accomplish the
commercialisation of our TB diagnostics, and making a significant impact in the field of diagnostic
medicine by further realising the full potential of the ProteinLogic proprietary technology
ImmiPrint®, in line with the commercial vison of the company.”

Nicolas Huber, ProteinLogic CEO, stated: “Darleen brings an extensive breadth and depth of
knowledge of the industry, as well as excellent knowledge of the regulatory landscape, which will
play a key role in the definition of our market-access strategy. In addition, moving into a more
commercial phase of the company, Darleen will ensure the high quality of our processes and our
products will make ProteinLogic a respectable player in IVDs. It is a pleasure to be welcoming
Darleen on board, and I am more than looking forward to be working with her moving forward.”

Further information:

info@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel diagnostic blood test for tuberculosis. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.

Amoxicillin clavulanate purchase

CAMBRIDGE, UK (2018-02-19) – ProteinLogic, the biomarker discovery company, has appointed Dr Nicolas Huber as its Chief Executive Officer.

Dr Huber holds a Masters degree in electronic engineering and a PhD in Space Science from the University of Sussex. After working in the aerospace sector he transitioned to the biomedical sciences, and over the past 8 years has been focused on medical device research and commercialization. Most recently he has developed a new portfolio of devices for the treatment of cancer, and built a product development team and new business line within an established multinational. Dr Huber during this time has also been working with several start-ups in the healthcare sector as a mentor, and providing them guidance on market access and positioning.

“This is a very exciting time to be joining ProteinLogic”, Nicolas commented. “Recent positive developments with the Tuberculosis (TB) diagnostic signature demonstrate that there is a robust and compelling opportunity to realise the medical and commercial vision of the Company. The potential of ProteinLogic’s proprietary immune profiling technology, ImmiPrint®, for the early detection and diagnosis of human diseases is significant.

The most recent analysis and independent validation of multiple samples from a large prospective cohort of TB patients shows that we have achieved, and indeed exceeded, the WHO’s Target Product Profile specifications for a TB rule-out test. This has considerable commercial potential, and the potential to address a healthcare issue of profound global medical significance. The latest data has provided a definitive validation of the Company’s core platform technology, and promises to be the first of many future successes.

My focus as the incoming CEO will be on four key areas, namely: strengthening the Company’s foundations, building a winning team, defining and executing a coherent growth strategy, and ensuring the Company’s long-term financial sustainability.

I am excited to be working with the Board of Directors on making progress on these, and growing ProteinLogic to become a prominent player in the thriving Biotechnology space.”

Mr Peter Klimt, acting Chairman of ProteinLogic, stated: “We are delighted to have Nicolas on-board. His experience in commercialising new medical devices, his understanding of the broader healthcare landscape, and his energy and personality are an excellent addition to ProteinLogic just as the company is entering a phase of intense focus on commercialisation of our proprietary technology. The Board and I are looking forward to working closely with Nicolas to deliver commercial success for our unique diagnostic solutions.”

Further information:

info@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel diagnostic blood test for tuberculosis. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.

48th Union World Conference on Lung Health in Guadalajara, Mexico

ProteinLogic attended the 48th Union World Conference on Lung Health held in Guadalajara, Mexico, held on 11th-14th October 2017.  The conference theme was  ‘Accelerating Toward Elimination’.

There was a focus on how to accelerate toward elimination of Tuberculosis. Numerous prominent scientists and global thought leaders emphasised the need for pro-active steps to find people with Active TB and the importance of blood based rule-out triage test for Active TB.

Delegates from more than 100 countries attended the four-day scientific programme of plenaries, symposia and abstracts presented by experts from around the world. The conference saw debate and discussion from public health professionals, researchers, scientists, civil society and the community.

Further information:

Mahesh Shah, ProteinLogic Ltd,

mahesh.shah@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in the blood and other body fluids.

In addition to the TB diagnostic test there are a number of potential follow-on products in the Company’s pipeline.

www.proteinlogic.com

Tadalafil 40 mg for sale

CAMBRIDGE, UK (2017-08-30) – ProteinLogic, a biomarker discovery company, funded by a grant by the European Union Horizon 2020 SME programme to develop a rapid point-of-care test for the diagnosis of Active Tuberculosis (TB), has achieved a significant milestone.

In 2015, 10.4 million people fell ill with TB and 1.8 million died from the disease. Over 95% of TB deaths occur in low and middle-income countries. Whilst TB incidence has fallen by an average of 1.5% per year since 2000, there is an urgent need to accelerate this to a 4–5% annual decline. The World Health Organisation has set a 2035 target of 95% reduction in deaths and a 90% decline in TB incidence – similar to current levels in low TB incidence countries today. To achieve this the WHO has called for the accelerated development of new tools for the diagnosis of TB. A panel of international experts on TB agreed that highest on their list of priorities was the development of a rule out test that can be used by first-contact health-care providers to identify those who need further testing (the triage test). Such a rule out test can also be used as a systematic screening test for active case-finding.

A rule out test for active TB has significant potential impact on TB transmission. By enabling the early identification of those symptomatic patients who do not have TB, healthcare professionals can focus on the smaller numbers who test positive to investigate further to diagnose and treat those with Active TB. Each person with Active TB can potentially spread the disease to many others thus feeding the cycle of transmission of the disease.

The ProteinLogic TB test comprises a unique panel of biomarker proteins tested on over 1600 clinical samples from S.Africa, Uganda, Vietnam, Peru and London. In a recent study analysing 500+ high quality clinical samples, ProteinLogic scientists have achieved a level of accuracy (measured by sensitivity, specificity, negative predictive value and positive predictive value) comfortably exceeding the WHO criteria for a rule out test.

Dr Alexander Betz, Chief Scientific Officer of ProteinLogic, commented “ProteinLogic has taken great care to use state of the art statistics and validation methodology and analysed the largest sample set to date exceeding anything published in the literature. In this latest study using over 500 well characterised prospective TB samples, we obtained results that meet and in fact exceed the target product profile for a rule out test set by the WHO. Whilst we need to do further validation studies to independently verify this, we are cautiously optimistic.”

 

ProteinLogic’s Chairman Mahesh Shah said: “We are excited by the results. This would not have been possible without the help and support of the European Commission in funding this exciting project. We would also like to thank FIND (Foundation for Innovate Diagnostics) who provided clinical samples and invaluable support. This is a significant step forward in the global fight to eradicate TB.”

The estimated market size for a Rule-Out Test for Active TB is estimated to be 80million tests per annum. Whilst India, China, South Africa and Indonesia represent almost 50% of the global market, there is also a sizeable market in Europe, US and Latin America with a market potential of over 5million tests per annum. The market potential varies according to the penetration of the test into decentralized settings and the patient populations or types of TB it detects. The ProteinLogic Test has also got the potential of being useful for the more difficult cases of extra-pulmonary TB and also Childhood TB.

Further information:

Mahesh Shah, ProteinLogic Ltd,

mahesh.shah@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in the blood and other body fluids.

In addition to the TB diagnostic test there are a number of potential follow-on products in the Company’s pipeline.

www.proteinlogic.com

Horizon 2020

Horizon 2020 is the financial instrument of the European Union, implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness. Horizon 2020 is the biggest ever EU research and innovation program. Through the SME Instrument, the European Union wants to finance the most innovative small companies with a high growth potential. The program promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.

By coupling research and innovation, Horizon 2020 is helping to drive economic growth with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.

Selected SMEs, showing a strong ambition to develop, grow and internationalise, shall be supported across Horizon 2020 with a dedicated instrument to provide staged and seamless support covering the whole innovation cycle.

For more information please visit http://cordis.europa.eu/programme/rcn/664237_en.html

Is viagra generic available in canada

CAMBRIDGE, UK (2016-05-03) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Alex Betz as Chief Scientific Officer to manage the scientific, research, technological and developmental operations. As a long standing non-executive director of the Company, Alex has helped set the company research and scientific priorities so that they line up with the overall mission and goals of the Company

Dr Betz completed a PhD on the hypermutation of immunoglobulin genes at the MRC Laboratory of Molecular Biology, Cambridge UK. After 3.5 years working as a post-doc at the Howard Hughes Medical Institute, Johns Hopkins University, Baltimore USA, he was recruited back to the MRC Laboratory of Molecular Biology. His initial research interest was the regulation of lymphocyte migration by chemokines. In 2004 he published his group’s breakthrough discovery that regulatory T cells maintain maternal tolerance to the fetus.  He retired from academic research in 2015 and now focuses on helping commercial projects.

Alex commented  “I am pleased to take on this role in ProteinLogic. I have been involved with the company from an early stage and am delighted to take on this role in developing its biomarker signature for Tuberculosis as well as a pipeline of other diseases. I am excited by the huge potential that ProteinLogic holds and look forward to shaping these opportunities and bringing tests to the market that can make a real impact to people’s health”.

ProteinLogic’s Chairman Mahesh Shah said: “We are delighted to welcome Alex to this new role at ProteinLogic. Whilst we have had the benefit of Alex’s scientific rigour as a NED, his appointment as Chief Scientific Officer will be a catalyst to the development of diagnostic tests and biomarker discovery programs. We look forward to working with him as he plays a significant role in the further development of the Company’s vision of developing a discovery platform for biomarkers and a point-of-care platform for the early diagnosis of Tuberculosis.”

 

Further information:

Mahesh Shah, ProteinLogic Ltd,

mahesh.shah@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel diagnostic blood test for tuberculosis. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.


www.proteinlogic.com

ProteinLogic appoints Dr Roslin Russell as VP Bioinformatics & Computational Biology

ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Roslin Russell as Vice President of Bioinformatics & Computational Biology to bring technical expertise in the execution of the company’s R&D strategy.

Before joining ProteinLogic, Roslin Russell spent eight years working for the Cambridge Institute, Cancer Research UK, as a computational biologist specialising in high-throughput data analysis: microarray, next generation sequencing and protein mass-spectrometry. With eighteen years’ experience in bioinformatics and computational biology she’s also been hands-on with wet-lab experiments and her research areas include parasitology and infectious diseases, immunology as well as oncology. Roslin will use her capabilities to develop and refine diagnostic algorithms and will also input into experimental design and the company’s R&D strategy.

Roslin comments: “I’m very thrilled to be part of the PL team. My background in immunology, cancer, infectious diseases and computational biology will be well-matched to PL’s research and development.”

ProteinLogic’s Chairman Mahesh Shah said: “We are delighted to welcome Roslin to her new role at ProteinLogic. Her appointment will strengthen the Company’s technical team and increase our bioinformatics and research development capacity. We look forward to working with her as she plays a significant role in the further development of the Company”.